Märkte & Kurse

CUREVAC NV
Suchanfrage Börsenlexikon
ISIN: NL0015436031 WKN: A2P71U Typ: Aktie DIVe: 0,00% KGVe: -
 
2,762 EUR
0,00
0,00%
Echtzeitkurs: 09.05.24, 22:26:44
Aktuell gehandelt: 46.702 Stk.
Intraday-Spanne
2,662
2,780
Handelsplatz wählen:
Perf. 1 Jahr -66,76%
Perf. 5 Jahre -
52-Wochen-Spanne
2,062
11,340
TARGOBANK Depot:
 
kaufen   verkaufen
Sparplan eröffnen:   Sparplan eröffnen:
Investment Tools:
Analysieren Sie Ihr Wertpapier im Detail mit unseren Tools.
RisikohinweiseProduktinformation
  Übersicht     Kennzahlen     Portrait     Analyse     Chart     Nachrichten     Hebelprodukte     Zertifikate     Fonds  
Ausgewählte Nachricht zu dieser Aktie
19.06.2023-

EQS-News: CureVac Announces Voting Results of General Meeting (deutsch)

CureVac Announces Voting Results of General Meeting

^
Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting

19.06.2023 / 17:30 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

CureVac Announces Voting Results of General Meeting

TÜBINGEN, Germany / BOSTON, USA - June 19, 2023 - CureVac N.V. (Nasdaq:
CVAC), a global clinical-stage biopharmaceutical company developing a new
class of transformative medicines based on messenger ribonucleic acid
("mRNA"), today announced the voting results of the Company's annual general
meeting.

The shareholders of the Company voted in favor of all proposals. The
proposals voted in favor for included the appointment of Michael Brosnan as
member of the Supervisory Board effective June 19th, 2023, and the
appointment of KPMG Accountants N.V. as the external auditors for the
financial year 2024.

A table containing tabulations of the votes casted is expected to be
released in the coming days.

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of
messenger RNA (mRNA) technology, with more than 20 years of expertise in
developing, optimizing, and manufacturing this versatile biological molecule
for medical purposes. The principle of CureVac's proprietary technology is
the use of optimized mRNA as a data carrier to instruct the human body to
produce its own proteins capable of fighting a broad range of diseases. In
July 2020, CureVac entered in a collaboration with GSK to jointly develop
new products in prophylactic vaccines for infectious diseases based on
CureVac's second-generation mRNA technology. This collaboration was later
extended to the development of second-generation COVID-19 vaccine
candidates, and modified mRNA vaccine technologies. Based on its proprietary
technology, CureVac has built a deep clinical pipeline across the areas of
prophylactic vaccines, cancer therapies, antibody therapies, and the
treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen,
Germany, and has more than 1,100 employees across its sites in Germany, the
Netherlands, Belgium, Switzerland and the U.S. Further information can be
found at www.curevac.com.

CureVac Media and Investor Relations Contact

Dr. Sarah Fakih, Vice President Corporate Communications and Investor
Relations

CureVac, Tübingen, Germany

T: +49 7071 9883-1298

M: +49 160 90 496949

sarah.fakih@curevac.com

Forward-Looking Statements CureVac

This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the
opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,
CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac
Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and
CureVac Netherlands B.V. (the "company") regarding future events or future
results, in contrast with statements that reflect historical facts. Examples
include statements regarding the completion, size and terms of the proposed
public offering. In some cases, you can identify such forward-looking
statements by terminology such as "anticipate," "intend," "believe,"
"estimate," "plan," "seek," "project," or "expect," "may," "will," "would,"
"could," "potential," "intend," or "should," the negative of these terms or
similar expressions. Forward-looking statements are based on management's
current beliefs and assumptions and on information currently available to
the company. However, these forward-looking statements are not a guarantee
of the company's performance, and you should not place undue reliance on
such statements. Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, including negative worldwide
economic conditions and ongoing instability and volatility in the worldwide
financial markets, ability to obtain funding, ability to conduct current and
future preclinical studies and clinical trials, the timing, expense and
uncertainty of regulatory approval, reliance on third parties and
collaboration partners, ability to commercialize products, ability to
manufacture any products, possible changes in current and proposed
legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company's industry, the
effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, reliance on key personnel, reliance on
intellectual property protection, ability to provide for patient safety, and
fluctuations of operating results due to the effect of exchange rates or
other factors. Such risks and uncertainties may cause the statements to be
inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company's control and
could cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this press release
are made only as of the date hereof. The company does not undertake, and
specifically declines, any obligation to update any such statements or to
publicly announce the results of any revisions to any such statements to
reflect future events or developments, except as required by law.

For further information, please reference the company's reports and
documents filed with the U.S. Securities and Exchange Commission (SEC). You
may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

---------------------------------------------------------------------------

Veröffentlichung einer Mitteilung, übermittelt durch EQS Group AG.
Medienarchiv unter https://www.eqs-news.com.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

Sprache: Deutsch
Unternehmen: CureVac
Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland
EQS News ID: 1660283


Ende der Mitteilung EQS News-Service
---------------------------------------------------------------------------

°
 
Weitere Nachrichten zu dieser Aktie
Seiten:  1 2 3    Anzahl: 46 Treffer     
Datum Zeit Nachrichtenüberschrift
24.04.2024 15:21 Höherer Verlust: Impfstoffhersteller Curevac will...
24.04.2024 13:06 EQS-News: CureVac veröffentlicht Finanzergebnisse...
24.04.2024 13:03 EQS-News: CureVac gibt Start einer kombinierten Ph...
24.04.2024 13:00 EQS-News: CureVac ernennt Thaminda Ramanayake zum ...
18.04.2024 13:00 EQS-News: CureVac veröffentlicht am 24. April 202...
16.04.2024 13:00 EQS-News: CureVac und MD Anderson gehen strategisc...
04.04.2024 13:00 EQS-News: CureVac gibt vielversprechende Interim-P...
17.03.2024 20:35 dpa-AFX-Überblick: UNTERNEHMEN - Die wichtigsten ...
17.03.2024 16:24 Impfstoffhersteller Curevac will 150 Stellen strei...
05.01.2024 13:00 EQS-News: CureVac veröffentlicht positive Interim...
27.12.2023 15:20 dpa-AFX-Überblick: UNTERNEHMEN vom 27.12.2023 - 1...
27.12.2023 14:02 Streit um Corona-Impfstoffpatent: Gericht vertagt ...
20.12.2023 14:06 AKTIE IM FOKUS: Curevac etwas weiter erholt vom Re...
19.12.2023 22:31 ROUNDUP/Aktien New York Schluss: Aussicht auf Zins...
19.12.2023 19:59 Aktien New York: Rally geht in neue Runde - Dow un...
19.12.2023 17:27 AKTIEN IM FOKUS 2: Curevac fallen - Patentstreit m...
19.12.2023 17:06 WDH/ROUNDUP: Bundesgericht erklärt Corona-Patent ...
19.12.2023 16:45 ROUNDUP/Aktien New York: Rally geht weiter - Dow u...
19.12.2023 16:37 ROUNDUP: Bundesgericht erklärt Corona-Impfstoffpa...
19.12.2023 15:41 AKTIE IM FOKUS: Curevac brechen ein - Patentstreit...

Börsenkalender 1M

22.05.24
Geschäftsbericht

Übersicht

 
Tagesroutine
Die Tagesroutine umfasst alle täglich wiederkehrenden Nachrichten, die vor, während und nach dem Börsentag veröffentlicht werden.
 

 
* Information zu Abkürzungen: HP = Handelsplatz
FactSet
Implemented and powered by FactSet. Bereitstellung der Kurs- und Marktinformationen erfolgt durch FactSet.
Bitte beachten Sie die Risikohinweise und Quellenangaben der TARGOBANK, die für diese Seite gelten.
 

 

Produkte und Services